Cancer Therapies continues to be one of the most active segments within the pharmaceutical industry. However, certain biological targets have long eluded drug development efforts. One such target is Ras family, which has been identified to play a critical role in oncogenesis. Scientific literature suggests that the RAS gene is mutated across about 30% of cancer types. Likewise, there are several other targets that have not yet been successfully drugged and researchers are making significant efforts to identify novel approaches to target them. Advances in drug discovery and development technologies / platforms have increased the likelihood of targeting a number of the aforementioned types of biological targets. As a result, novel product development opportunities have emerged and are likely to benefit both drug developers and investors alike.
Several Drugs are Under Development Against a Variety of Undruggable Targets
Recent advances have enabled researchers to design drugs against various undruggable targets; over 100 such molecules are presently under development
The Relative Popularity of These Targets, Evidenced by Industry / Academic Interest, Vary
Specific targets have emerged as more prominent based on the overall score evaluated on both industry and academic involvement
Published Literature Validates the Growing Interest in this Field
An analysis of published literature and grants awarded by government bodies reveals that the primary focus is currently on the Ras family of GTPases
North America and Europe are the Key Innovation Hubs
Over 80% of drug developers engaged in this field are located in North America and Europe; South East Asia is also emerging as a popular hub
Novel Technology Platforms are Amongst the Vital Enablers
Several players across the globe have developed novel technology platforms to support initiatives related to drugs against difficult-to-modulate targets
We Expect the Market to Grow at an Accelerated Pace in the Long Term
Prevalent trends indicate that the market is poised to grow significantly as late stage molecules are likely to get approved for different indications
The Opportunity is Likely to be Well Distributed Across Different Targets, …
Advancements in the field will present opportunities across various target families as well as drugs designed to be administered via different routes.
… Types of Molecules and Regions Worldwide
Overall, the growth is anticipated to be spread across multiple type of molecules and different geographical regions.
Arun is an enthusiastic professional and has been associated with Roots Analysis since the very early years. He has led multifaceted roles over the years be it business research, consulting, competitive intelligence, IT & technology, sales and marketing. He currently drives strategic thinking and execution within the sales and marketing domain. With educational background in life sciences from Thapar University and digital marketing credentials from Indian School of Business, he has led a lot of critical initiatives at the organization. His background in life sciences has been one of the key reasons for quick understanding and implementation of customized marketing strategies. During his early years, he has led multiple consulting assignments for global clients ranging from competitive landscaping, deal structuring and preparing go-to-market strategy for his clients.